Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study

Allergy and Asthma Proceedings

Volumn 36, Issue 1, 2015, Pages 40-47

  Klimek, Ludger ^a   Bachert, Claus ^b   Mösges, Ralph ^c   Munzel, Ullrich ^d   Price, David ^e   Virchow, J Christian ^f   Wahn, Ulrich ^g   Bousquet, Jean ^h  

^a Center for Rhinology and Allergology   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MEDA Pharma   (Germany)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE PLUS FLUTICASONE PROPIONATE; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; DRUG COMBINATION; MP29-02; PHTHALAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; APPLICATION SITE PAIN; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; DYSGEUSIA; EYE BURNING; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRAINE; MULTICENTER STUDY; NAUSEA; NOSE IRRITATION; NOSE OBSTRUCTION; PROSPECTIVE STUDY; RHINITIS; RHINORRHEA; SIDE EFFECT; SNEEZING; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT; YOUDEN INDEX; YOUNG ADULT; CLINICAL TRIAL; DRUG COMBINATION; PRESCHOOL CHILD; RETREATMENT; RHINITIS, ALLERGIC; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHTHALAZINES; PROSPECTIVE STUDIES; RETREATMENT; RHINITIS, ALLERGIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919741343     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3823     Document Type: Article

References (36)

1. Antonescu E, Childres N, Gardini E, et al. Written declaration on recognising the burden of allergic disease. European Parliament. 2014.
2. Bousquet J, Khaltaev N, Cruz AA, et al.; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, et al.; Global Allergy and Asthma European Network, Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126:466-476, 2010.
4. Wallace DV, Dykewicz MS, Bernstein DI, et al.; Joint Task Force on Practice; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl):S1-S84, 2008.
5. Price D, Bousquet J, Pitman R, et al. Sub-optimal control of allergic rhinitis: The need for a new and more effective treatment option. Allergy 68(Suppl 97):A405, 2013.
6. Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 160:393-400, 2013.
7. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 161:369-377, 2013.
8. Ciprandi G, Incorvaia C, Scurati S, et al. Patient-related factors in rhinitis and asthma: The satisfaction with allergy treatment survey. Curr Med Res Opin 27:1005-1011, 2011.
9. Navarro A, Valero A, Rosales MJ, and Mullol J. Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol 21:363-369, 2011.
10. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 62(suppl 85):17-25, 2007.
11. Price D, Scadding G, Bachert C, et al. Dynamics of treatment within a year in patients diagnosed with either allergic, non-allergic rhinitis or hay fever over the period 1992-2012. Allergy 69(Suppl 99):A284, 2014.
12. Scadding GK, Durham SR, Mirakian R, et al.; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 38:19-42, 2008.
13. Costa DJ, Amouyal M, Lambert P, et al.; Languedoc-Roussillon Teaching General Practitioners Group. How representative are clinical study patients with allergic rhinitis in primary care? J Allergy Clin Immunol 127:920-926.e1, 2011.
14. Price D, Papadopoulos N, Scadding G, et al. Assessing allergic rhinitis symptom control: Results from a digital survey conducted during EAACI 2013. Presented at European Academy of Allergy and Clinical Immunology Congress, Copenhagen, Denmark, June 7-11, 2014.
15. Bousquet J, Addis A, Adcock I, et al.; European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy, WP 10; Global Alliance against Chronic Respiratory Diseases. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 44:304-323, 2014.
16. Bousquet PJ, Combescure C, Klossek JM, et al. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 123:1349-1354, 2009.
17. Bousquet J, Bachert C, Canonica GW, et al.; ACCEPT-1 Study Group. Efficacy of desloratadine in intermittent allergic rhinitis: A GA(2)LEN study. Allergy 64:1516-1523, 2009.
18. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 62:367-372, 2007.
19. Bousquet J, Bachert C, Canonica GW, et al.; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis - A GA(2)LEN study. Int Arch Allergy Immunol 153:395-402, 2010.
20. Dymista summary of product characteristics. Available online at www.medicines.org.uk/emc/medicine/27579; accessed October 24, 2014.
21. German Drug Law. Gesetzuber den Verkehr mit Arzneimitteln. Arzneimittelgesetz in der Fassung der Bekanntmachung vom 1. Dezember 2005 (BGBl.IS. 3394), das durch Artikel 2a des Gesetzes vom 27.Muml]arz 2014 (BGBl.IS. 261) geändert worden ist, 1976.
22. BfArM/PEI. Empfehlungen des Bundesinstituts fur Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchfuhrung und Auswertung von Anwendungsbeobachtungen. July 7, 2010. Taking into consideration the Third Act to amend pharmaceutical legislation and other regulations, dated August 2013 (BGBl.I S. 3108), 2010.
23. Demoly P, Bousquet PJ, Mesbah K, et al. Visual analogue scale in patients treated for allergic rhinitis: An observational prospective study in primary care: Asthma and rhinitis. Clin Exp Allergy 43:881-888, 2013.
24. Acaster S, Ali S, Breheny K, et al. Treatment preferences in patients with moderate/severe seasonal allergic rhinitis: Findings of a discrete choice experiment. Allergy 67(Suppl 96):A891, 2012.
25. Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:264-271, 2008.
26. Esteitie R, deTineo M, Naclerio RM, and Baroody FM. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 105:155-161, 2010.
27. Hellgren J, Cervin A, Nordling S, et al. Allergic rhinitis and the common cold-high cost to society. Allergy 65:776-783, 2010.
28. Fang SY, Perng DW, Lee JY, et al. An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. Chin J Physiol 53:199-207, 2010.
29. Adham TM. Treatment of allergic rhinitis with desloratadine: Results of a multinational observational study in the Middle East gulf region. World Allergy Organ J 4:130-134, 2011.
30. Sonnemann U, Moller M, and Bilstein A. Noninterventional open-label trial investigating the efficacy and safety of ectoine containing nasal spray in comparison with beclomethasone nasal spray in patients with allergic rhinitis. J Allergy (Cairo) 2014:297203, 2014.
31. Pitsios C, Papadopoulos D, Kompoti E, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 96:673-678, 2006.
32. Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 23:495-503, 2013.
33. EMA Guideline. Guideline on the clinical development of medicinal products for the treatment of allergic rhinocon-junctivitis. Available online at www.ema.europa.ed/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003554.pdf; last accessed December 2, 2014.
34. Bousquet J, Bachert C, Price D, et al. Assessing allergic rhinitis symptom control using a simple visual analogue scale: the digital solution. Allergy 69(Suppl 99):A277, 2014.
35. Ohta K, Bousquet JP, Akiyama K, et al. Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan. J Asthma 50:514-521, 2013.
36. Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial. J Allergy Clin Immunol 126:666-668.e1-5, 2010.